A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer

Journal of Medical Economics

Volumn 14, Issue 2, 2011, Pages 179-186

  Nelson, Michael A ^a   Shetty, Sharash ^a   Kulakodlu, Mahesh ^a   Harley, Carolyn ^a   Seal, Brian ^b  

^a i3 Innovus   (United States)

^b SANOFI   (France)

Author keywords

Chemotherapy; Colorectal neoplasms; Drug costs; FOLFOX regimen; IFL protocol; Mortality

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL SURGERY; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL RECORD REVIEW; METASTASIS; OUTCOME ASSESSMENT; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; FLUOROURACIL; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 79952998099     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2011.556693     Document Type: Article

References (16)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society, 2009
2. Jansman FGA, Postma MJ, Brouwers JRBJ. Cost considerations in the treat-ment of colorectal cancer. Pharmacoeconomics 2007;25:537-62 (Pubitemid 47048039)
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer; 2008. Available at: www.nccn.org. Last accessed July 1, 2010
4. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: cur-rent options, current evidence. J Clin Oncol 2005;23:4553-60 (Pubitemid 46196586)
5. Pasetto LM, Jirillo A, Iadicicco G, et al. FOLFOXversus FOLFIRI: acomparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res 2005;25:563-76 (Pubitemid 40476102)
6. Hillner BE, Schrag D, Sargent DJ, et al. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 2005; 104:1871-84 (Pubitemid 41513170)
7. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated health care costs: a retrospective analysis among managed care patients with chronic myelogenous leukemia. Pharmacoeconomics 2007;25:481-96 (Pubitemid 46849189)
8. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999-2008, Medical Care. Series ID: SUUR0000SAM. Washington, DC: U.S. Dept. of Labor, Bureau of Labor Statistics, 2008. http://data.bls.gov/cgi-bin/surveymost?su
9. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27 (Pubitemid 128456396)
10. Charlson ME, Pompei P, Ales KL, et al. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83 (Pubitemid 17055592)
11. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol1992;45:613-19
12. Manning W, Mullahy J. Estimation log models: to transform or not to trans-form? J Health Econ 2001;20:461-94 (Pubitemid 32515166)
13. Owens D. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998;13:716-17 (Pubitemid 28473801)
14. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30 (Pubitemid 41095110)
15. Tournigand C, Andrè T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37 (Pubitemid 41095086)
16. Tumeh JW, Shenoy PJ, Moore SG, et al. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer. Am J Clin Oncol 2009; 32:49-55